HPC Offered for PRESERVE Expansion

Allogeneic bone marrow transplantation is a highly effective and time-tested treatment for an array of hematologic diseases. However, far too many of the patients that could benefit from a bone marrow transplant are unable to receive one due to inadequate access to bone marrow donors.

At Ossium, we envision a future in which every blood cancer patient has access to a bone marrow donor. In pursuit of this vision, we’ve established a first-of-its-kind bank of cryopreserved organ donor-derived bone marrow to dramatically expand patient access to bone marrow transplantation.

We recently launched the PRESERVE I clinical study of our bone marrow product in acute leukemia patients who require an allogeneic bone marrow transplant. Through this multi-center clinical study, acute leukemia patients who don’t have a suitable living donor have a new opportunity to receive a bone marrow transplant.

We recognize that there are many patients in need of a bone marrow donor that cannot participate in the PRESERVE I study due to its eligibility criteria or for logistical reasons. For these patients, it may feel like there is no hope. To serve these patients and further our company mission, we’ve launched the Ossium HOPE Program. Through this program, we’re expanding access to our bone marrow product to patients outside of the PRESERVE I study.

Patients aged 18-70 may be eligible to receive bone marrow for transplantation through the Ossium HOPE Program* if:

  • They were diagnosed with a blood cancer
  • Their treating physician determined they are eligible for allogeneic bone marrow transplant
  • Their treating physician determined that the potential benefit outweighs the potential risks

Patients, their family or friends, and healthcare providers may request information about participating in the Ossium HOPE Program by submitting information in the form below.

Your phone number
Who are you filling this form out on behalf of?(Required)
Is there anything else you want to share about why you’re interested in the HOPE Program?
This field is for validation purposes and should be left unchanged.

* Ossium reserves the right to discontinue or change the terms of the Ossium HOPE Program (including the key patient criteria) at any time in its sole discretion. Ossium reserves the right to make the final determination regarding whether a patient meets the key patient criteria for the Ossium HOPE Program in its sole discretion.